Bone health

Dispute over influence of drug industry dinners on prescribing

Claims that pharmaceutical industry-sponsored events are promoting osteoporosis overdiagnosis and influencing prescribing have been rejected by a leading endocrinologist. An Australian study of 1,375 industry-sponsored events related to osteoporosis between 2011 and 2015 found sponsorship was highly concentrated into a few companies. Amgen and GSK, which co-marketed denosumab at the time of the study*, together sponsored ...

Already a member?

Login to keep reading.

© 2022 the limbic